Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences

Jacqueline Dickson, PhD, Nick Kennedy, MBBS MA Cantab FRACP, Leanne M. Cork, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Corinne A. Hedgley, BSc (Hons), Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Tessa L. Holyoake, MDPhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Bernard Ramashoye, PhDMRCP FRCPath

Blood (2015) 126 (23): 4021.

https://doi.org/10.1182/blood.V126.23.4021.4021

Published: 2015

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Corinne Hedgley, BSc, Sarah Adams, BSc MSc, Letizia Foroni, MDPhD, Jane F. Apperley, MD, Tessa L Holyoake, MDPhDFRSE FMedSci, Christopher Pocock, MD PhD, Jenny L Byrne, MB ChB PhDFRCP FRCPath, Lynn Margaret Seeley, MSc RN NDN, Wendy L Osborne, MBBS(Hons) MRCP FRCPath, John M Goldman, DM, Mhairi Copland, BSc PhDFRCP FRCPath, Richard E Clark, MA, MD

Blood (2014) 124 (21): 517.

https://doi.org/10.1182/blood.V124.21.517.517

Published: 2014

Journal Articles

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Jorge E. Cortes, MD, H. Jean Khoury, MD, Andreas Hochhaus, MD, Jane F Apperley, MD, Stephen G. O'Brien, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Maureen G. Conlan, MD, Hagop M. Kantarjian, MD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 1484.

https://doi.org/10.1182/blood.V122.21.1484.1484

Published: 2013

Journal Articles

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

Jane F Apperley, MD, Richard M Szydlo, PhD, Gareth Gerrard, PhD, James R McCue, Jamie Wardle, Richard E Clark, MD, Stephen G O'Brien, Letizia Foroni, MD

Blood (2013) 122 (21): 93.

https://doi.org/10.1182/blood.V122.21.93.93

Published: 2013

Journal Articles

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

Sara Ali, Ruhena Sergeant, Stephen G. O'Brien, Letizia Foroni, Corinne Hedgley, Gareth Gerrard, Dragana Milojkovic, Kate Stringaris, Ahmad Khoder, Abdullah Alsuliman, Maria Gilleece, Ian H. Gabriel, Nichola Cooper, John M. Goldman, Jane F. Apperley, Richard E. Clark, David Marin, Katayoun Rezvani

Blood (2012) 120 (3): 697–698.

https://doi.org/10.1182/blood-2012-04-421016

Published: 2012

Journal Articles

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators

Blood (2010) 116 (19): 3758–3765.

https://doi.org/10.1182/blood-2010-03-273979

Published: 2010

Journal Articles

A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Shannon K. McWeeney, Lucy C. Pemberton, Marc M. Loriaux, Kristina Vartanian, Stephanie G. Willis, Gregory Yochum, Beth Wilmot, Yaron Turpaz, Raji Pillai, Brian J. Druker, Jennifer L. Snead, Mary MacPartlin, Stephen G. O'Brien, Junia V. Melo, Thoralf Lange, Christina A. Harrington, Michael W. N. Deininger

Blood (2010) 115 (2): 315–325.

https://doi.org/10.1182/blood-2009-03-210732

Published: 2010

Includes: Supplemental data

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Richard A. Larson, MD, Yen Lin Chia, PhD, Camille Granvil, PhD, François Guilhot, MD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Michele Baccarani, MD, Timothy P. Hughes, MD, MBBS, Jerry R. Nedelman, PhD, Yanfeng Wang, PhD

Blood (2009) 114 (22): 2213.

https://doi.org/10.1182/blood.V114.22.2213.2213

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P Hughes, MD, Andreas Hochhaus, MD, Susan Branford, PhD, Martin C Müller, MD, Letizia Foroni, MD, PhD, FRCPath, Brian J. Druker, MD, François Guilhot, MD, Richard A. Larson, MD, Stephen G O’Brien, MD, PhD, Roger J. Waltzman, MD, Manisha Mone, PhD, Elisabeth Wehrle, PhD, Jerald P. Radich, MD, John M. Goldman, MD

Blood (2008) 112 (11): 334.

https://doi.org/10.1182/blood.V112.11.334.334

Published: 2008

Journal Articles

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G O’Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, M.Sc., Brian J. Druker, MD, Richard A. Larson, MD

Blood (2008) 112 (11): 186.

https://doi.org/10.1182/blood.V112.11.186.186

Published: 2008

Journal Articles

Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation.

Joerg Hasford, Michael Lauseker, Insa Gathmann, Markus Pfirrmann, PhD, Richard A. Larson, MD, François Guilhot, Stephen G O’Brien, Brian J. Druker, Ruediger Hehlmann, Andreas Hochhaus, MD, For the IRIS Study Group, For the German CML Study Group

Blood (2008) 112 (11): 2123.

https://doi.org/10.1182/blood.V112.11.2123.2123

Published: 2008

Journal Articles

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang

Blood (2008) 111 (8): 4022–4028.

https://doi.org/10.1182/blood-2007-10-116475

Published: 2008

Includes: Supplemental data

Journal Articles

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Blood (2008) 111 (4): 1834–1839.

https://doi.org/10.1182/blood-2007-04-083196

Published: 2008

Journal Articles

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A. Schiffer, Jorge Cortes, Dietger W. Niederwieser, Carlo Gambacorti-Passerini, Richard M. Stone, John Goldman, Thomas Fischer, Stephen G. O'Brien, Jose J. Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian

Blood (2008) 111 (3): 1039–1043.

https://doi.org/10.1182/blood-2007-07-103523

Published: 2008

Journal Articles

Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia

Udo Holtick, Scott R. Marshall, Stephen G. O'Brien, Matthew P. Collin

Blood (2007) 110 (13): 4622–4623.

https://doi.org/10.1182/blood-2007-09-111757

Published: 2007

Journal Articles

IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Andreas Hochhaus, MD, Brian J. Druker, MD, Richard A. Larson, MD, Stephen G. O’Brien, MD, PhD, Insa Gathmann, Francois Guilhot, MD

Blood (2007) 110 (11): 25.

https://doi.org/10.1182/blood.V110.11.25.25

Published: 2007

NARROW

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation.

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia

IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only